


### **Interimreport** September 30, 2005

NEXUS AG, Villingen-Schwenningen



### Letter to our stockholders

Dear Stockholders:

"Medicine in Focus" is the message, with which we are introducing the change of our company look and the clear communication of our essential market message.

NEXUS has positioned its brands nexus/medfolio, nexus/inovit, nexus/gmt, nexus/medicare und nexus/it more clearly with respect to looks and contents. Thanks to the respective connection with the name NEXUS and the same layout, the membership in the Group is communicated clearly in addition to technical integration. Consequently, the strategy and the focusing of the company on medical information systems are represented actively on the market. We are convinced that the new look is an essential step to increase market acceptance and promote integration of the acquired products and organizations at the same time.

We are extremely satisfied with the integration successes of the last few months. We have not only been able to achieve our objectives with respect to contents and technology, but also with respect to effects on our net income and sales.

We have been able to complete our plans completely and improve them considerably compared to the previous year during the reporting period of January to September of the current year. Sales increased from EUR 10.2 million to EUR 15.1 million (+49%) during this period. The area of Health Care Software has been decisive, which grew by approx. 77% from EUR 6.4 million to EUR 11.4 million. Sales especially increased in Germany and Switzerland, and the sales figures include those of nexus/gmt GmbH, Frankfurt since May 1, 2005.

The operating result improved substantially analogue to the increase in sales. The EBITDA was KEUR 2,548 in the first nine months following KEUR 1,318 in the same period of the previous year (+ KEUR 1,230). The operating result before taxes improved from KEUR -586 KEUR +224 in the first nine months. The operating result before taxes also improved from KEUR -64 to KEUR +15 within the third quarter. The Group result also improved substantially from KEUR -822 KEUR +21 in the first nine months.

In spite of the good results of the first three quarter, we still have to put all our energy into maintaining our plans in the remaining months.

#### Highlights Group Sales and Result

- + 49% increase in sales in the first nine months 2005 from KEUR 10,152 to 15,102
- + Increase in sales in the Health Care Software Division by 77% to KEUR 11,355. (2004: KEUR 6.417)
- + EBITDA increases by KEUR 1,230 to KEUR 2,548 (2004: KEUR 1,318)
- + Result before taxes 09/05: improves by KEUR 810 to KEUR 224 (2004: KEUR -586)
- + Liquid funds increased to KEUR 19,486 due to high operative cash flow (+ KEUR 2,792)

This applies especially against the background of the substantial investments, which we want to make in the marketing and sales areas over the coming months. It is a question here of taking advantages of chances offered on the market and investing in the market and growth now.

As we have shown in the past, it pays to have a long-term strategy and convince our customers and those interested that NEXUS is a reliable and innovative partner. We remain convinced that it is worth the effort to take a bigger position in this growth market and to be equipped for the future.

KHORN'ST.


Dr. Ingo Behrendt CEO NEXUS AG



Dr. Ingo Behrendt CEO NEXUS AG

# Sales and Result Improved again

NEXUS Group sales increased from **KEUR 10,152** to **KEUR 15,102** (+48.8%) in the first nine months of the year 2005. Sales increased from **KEUR 3,839** to **KEUR 5,230** (+36.2%) in the third quarter. The increase in sales in due to inclusion of the nexus/gmt GmbH in the group financial statements on one hand, and on the other hand due to strong demand in the first nine months of the business year.



Sales in the segment of "Health Care Software" increased by 77% from **KEUR 6,417** to **KEUR 11,355** compared to the same period of the previous year.

Sales could be maintained at the same level of the previous year at **KEUR 3,748** in the segment of "Health Care Service" thanks to a strong third quarter.

Sales by Divisions								
KEUR	01.01	01.01	Δ	01.07	01.07	Δ		
KEOK	30.09.2005	30.09.2004	in %	30.09.2005	30.09.2004	in %		
Health Care Software						46,8		
Health Care Service	3.748	3.735	0,3	1.489	1.290	15,4		
Total :	15.102	10.152	48,8	5.230	3.839	36,2		

Sales in "Health Care Software" increased by 46.8% compared to the same quarter of the previous year from **KEUR 2,549** to **KEUR 3,741**.

Sales increased by 15.4% from KEUR **1,290** to **KEUR 1,489** in the segment of "Health Care Service" thanks to a strong third quarter.


Sales according to regions show a substantial improvement in Germany (+60.8%).

Sales in countries outside of Germany increased by 6.5%. This is above all due to further increases of our market share in Switzerland. Sales decreased considerably in Austria due to accounting procedures. The share of sales outside of Germany decreased overall from 23% to 16%.

Sales by I	Region	S				
KEUR	01.01 30.09.2005	01.01 30.09.2004	∆ in %	01.07 30.09.2005	01.07 30.09.2004	∆ in %
Germany				4.520	3.042	48,6
Switzerland	1.384	993	39,4	441	464	-5,0
Austria	203	355		108	117	-7,7
Italy	367	100	*	23	27	*
Rest of Europe/USA	368	162	*	113	64	*
Kuwait	77	644		25	125	*
Total :	15.102	10.152	48,8	5.230	3.839	36,2


# **Results** in the First Nine Months 2005

The positive development of the operating result continued during the reporting period. For example, the **EBITDA** increased by **KEUR 1,230** (previous year: KEUR 1,318) to **KEUR 2,548** in the first nine months. This reflects the increased demand for products of the NEXUS Group and the consistent use of synergy potential within the Group.



The Group result before taxes improved by **KEUR 810** to **KEUR 224** (previous year: KEUR -586). The result after taxes improved analogue by **KEUR 843** to **KEUR 21** (previous year: KEUR - 822).

#### GROUP RESULT BEFORE TAXES In KEUR + 810 first nine months



The result in the segment of "Health Care Software" increased by **KEUR 519** to **KEUR 154** (previous year: KEUR -365) in the first nine months.

The reversal of the trend in the segment of "Health Care Service" has been approved further. Consequently, the result in this area improved considerably by **KEUR 324** to **KEUR -133** (previous year: KEUR -457).

The operating result before taxes of the NEXUS Group improved by **KEUR 79** to **KEUR 15** (previous year: KEUR -64) in the third quarter.

The EBITDA developed in the same way and was higher by KEUR 82 at **KEUR 799** than in the semiannual report. This development confirms the positive trend of the NEXUS Group of the first halfyear.

The **cash** flow from current transactions increased by **KEUR 671** from KEUR 3,129 to **KEUR 3,800** compared to the previous year. The Group continues to have a large amount of cash funds. **Cash reserves** amounted to **KEUR 19,486** on the cut-off date (Dec. 31, 2004: KEUR 16,694).

#### Highlights Group Sales and Result

- + Increase of Group sales by 49% to KEUR 15,102
- + Increase of quarter sales by 36% to KEUR 5,230
- + Sales increase of 77% in "Health - Care Software"
- + Sales increase in Germany (+61%) and other countries (+7%)
- + Result improved by KEUR 519 in "Health Care Software"
- + Reversal of trend solidified in "Health Care Service".
- + Increase of operative cash flow by KEUR 671 to KEUR 3,800
- + Substantial cash reserves as previously

# **NEXUS** in the Environment of Financial and Health Markets

#### Price of NEXUS-shares Consolidated



Prices of NEXUS stocks experienced a continual upward trend during the first nine months. Starting from a price of  $\in$  2.05 at the beginning of the year, it increased to  $\in$  4.80 on the cut-off date.

#### **NEXUS MAINTAINS CONTACT**

Regardless of whether you want paper or electronic documents from NEXUS, we provide you with the requested information. E-mail us at <u>mail@nexus-ag.de</u>, and you will receive our financial reports or product information as soon as possible. These documents are available for downloading from our homepages <u>www.nexus-ag.de</u>. If you would like information on the telephone, you can call our Investor Relations Team at 07721-8482-320.

#### Finance and Event Schedule 1st Half-Year 2006

#### **Finance schedule**

Annual Report 2005 March 31, 2006

Quarterly Report Q1 / 2006 May 19, 2006

#### Event and trade fair schedule

Lucerne Health Trend Days March 20 - 24, 2006

ITeG, Frankfurt May 30 - June 1, 2006

#### Decisions in Favor of NEXUS in the 3rd Quarter

#### **Complete Solution**

- Krankenhaus Schleiz
- FLT Berlin
- Kantonsspital Biel


#### Ward Solution

- RNS, Wiesbaden
- Dürenhof, Bayreuth
- Krankenhaus der Augustinerinnen, Cologne
- Prosperhospital, Recklinghausen
- Zum Heiligen Kreuz, Vienna
- Elisabethenkrankenhaus, Mönchengladbach

### **NEXUS** Outlook and Group Information

#### NUMBER OF EMPLOYEES DECREASED DUE **TO INTEGRATION**

The number of employees was 208 persons as of September 30, 2005. A total of 204 persons were employed in the same period of the previous year. New employees were integrated and process workflows could be optimized within the wake of integrating GMT GmbH, Frankfurt.



#### DIRECTORS HOLDINGS

The director's holders of the supervisory board and the executive board are as follows on September 30. 2005 in comparison the previous year:

#### OUTLOOK

The positive development of the first three quarters demonstrated impressively that NEXUS AG is able to grow profitably and achieve its objectives. We have developed consistently had proved over the past years that success is possible on this difficult but attractive market with a long-term strategy and high-quality product development.

We set a number of milestones for this year, which we intend to achieve. First, we have to continue our communication offensive includina repositioning consistently to the end. This includes expanded communication on the market and an active form of regular customer information in addition to rearranging marketing tools.

We also have a number of objectives, which we still have to achieve, in the area of new products. This includes uniform Group medication software as well as the further development of the Dot.net versions and completing our new cardiology module.

We have to make the profile of NEXUS even sharper in our look and with our innovations over the coming months. While doing this, we have to improve our economic basis even further despite substantial investments. These are challenges, which we are glad to face and which provide incentives for us to improve our performance even more

Directors' Holdings			
	Number of stocks owned	Number of options	
Supervisory Board			
Dr. jur. Hans-Joachim König	81.099 Previous year: 81.099	81.099 Previous year: 81.099	
Dr. Herwig Freiherr von Nettelhorst	0 Previous year: 0	0 Previous year: 0	
Ronny Dransfeld	0	0	
Dr. Dietmar Kubis	Previous year: 0 0 Previous year: 0	Previous year: 0 0 Previous year: 0	
Prof.Dr. Ulrich Krystek	0 Previous year: 0	0 Previous year: 0	
Wolfgang Dörflinger	0 Previous year: 0	0 Previous year: 0	
Executive Board			
Dr. Ingo Behrendt	82.000 Previous year: 40.000	150.000 Previous year: 60.000	
Stefan Burkart, MRA	116.147	0	

# Facts and Figures Consolidated balancesheet as of September 30, 2005 and December 31, 2004 (IFRS)

#### ACOUNTING AND VALUATION METHOD

This interim report from the NEXUS Group as of September 30<sup>th</sup> 2005 has been prepared in keeping with the International Financial Reporting Interpretations (IFRS). The interpretation of the International Financial Reporting Interpretation Committee (IFRIC) has been taken into account.

The same accounting and valuation methods were used in the interim accounts as in the consolidated financial statements of the business year 2004. The report has not been audited.

	01.01.2004	01.01.2005
Assets	31.12.2004	30.09.2005
Annex	KEUR	KEUR
A. Short Term capital	NEON	neon
I. Cash and cash equivalents	2.769	4.620
II. Securities	13.925	14.866
	16.694	19.486
III. Receivables and other assets	10.034	19.400
1. Trade receivables	6.052	5.146
2. Receivables from associates companies	24	145
3. Other assets	3.909	2.887
4. Tax refund claims	383	272
	10.368	8.450
IV. Inventories	680	444
V. Prepared expenses	78	128
Total short term capital:	27.820	28.508
B. Long Term capital		
I. Property, plant and equipment		
1. Tenant Installations		
2. Other equipment, factory and office equipment	451	415
	451	415
II. Intangible assets		
1. Concessions, industrial property and rights and assets	439	
as well as licenses from such rights and assets		
2. Development costs	7.296	8.111
	7.735	8.111
III. Financial assets		
1. Investments in associates	62	57
2. Other loans	43	43
IV. Goodwill	105	100
1. Goodwill	5.221	5.659
2. customer base / technology	2.169	2.032
V. Deferred taxes	4.281	4.050
Total assets:	47.782	48.875

# Facts and Figures Consolidated balancesheet as of September 30, 2005 and December 31, 2004 (IFRS)

Liabilities and Equity		01.01.2004 31.12.2004	01.01.2005
	Annex	KEUR	KEUR
A. Short Term Liabilities			
I. Tax provisions		6	7
II. Other provisions		1.595	1.625
III. Bank loans		184	128
IV. Received payments for orders		998	691
V. Trade accounts payable		1.874	1.970
VI. Liabilities with associated companies		47	19
VII. Other liabilities		1.085	2.060
VIII. Deferred income		123	597
Total short term I	iabilities:	5.912	7.097
Pension provisions		405	424
Minority interest		440	343
3. Equity			
I. Subscribed capital		13.720	13.720
II. Capital reserves		38.898	38.854
III. Other reserves		1	1
IV. Equity capital difference from currency conversion		3	4
V. Validation reserve for financial instruments		75	83
VI. Consolidated loss cary forward		-11.199	-11.672
VII. Group loss		-473	21
Tot	al equity:	41.025	41.011
		47.782	48.875

### Facts and Figures Group Profit and Loss Account as of September 30, 2005 and September 30, 2004 (IFRS)

	01.07.2004	01.07.2005	01.01.2004	01.01.2005
	-30.09.2004	-30.09.2005	-30.09.2004	-30.09.2005
	KEUR	KEUR	KEUR	KEUR
1. Revenue	3.839	5.230	10.152	15.102
2. Increase/decrease in finished goods and work in progress	214	-46	543	-431
3. Own work capitalized	648	970	2.465	2.632
4. Other operating income	1.030	29	1.435	770
5. Cost of materials				
a) cost of raw materials, consumables and goods for resale	971	1.217	2.415	3.112
b) Cost for purchased services	337	457	618	1.104
6. Personnel costs				
a) Wages and salaries	2.866	2.307	6.616	6.956
b) Social costs	457	428	1.179	1.309
<ol><li>Depreciation and amortization of fixed intangible and tangible assets</li></ol>	658	871	1.993	2.620
8. Other operating expenses	580	1.021	2.621	3.141
9. Other taxes	2	4	8	9
10. Expenses from associated companies	0	0	0	
11. Other interest and similar income	116	144	358	432
12. Revenue from associated companies	0	0	0	0
13. Write-offs of financial assets	0	0	35	6
14. Interest payable and other similar charges	40	7	54	24
Profit before tax:	-64	15	-586	224
15. Income taxes	-78	-139	-406	-300
Profit after tax:	-142	-124	-992	-76
16. Minority interest	45	46	170	97
Group result:	-97	-78	-822	21
Earnings per share				
Weighted average of issued shares (in thousands)	11.816	13.720	11.816	13.720
Result per share in EUR (diluted and undiluted)	-0,01	-0,01	-0,07	0,00

# Facts and Figures Consolidated Cash flow statement as of September 30, 2005 and September 30, 2004 (IFRS)

	IFRS 01.01.2004 - 30.09.2004	IFRS 01.01.2005 - 30.09.2005
	KEUR	KEUR
. Cash flow from operating activities		
Results of the year before deduction of profit payable to other shareholders, income taxes,	-855	-177
interest and finance income/expenditure		
Depreciation and amortization	1.993	2.620
Other expenses/income with no impact on cash Profit / loss disposal of securities	-99 -35	83 -100
Increase / decrease in inventories	-667	-100
	001	0/1
Increase / decrease in trade receivables and other assets that cannot be allocated to investing or financial activities	508	1.181
Changes in provisions	73	-2
Increase / decrease in trade receivables and other liabilities that cannot be allocated to	1.804	-617
investing or financial activities	1.004	-017
Interest paid	-54	-54
interest payment received	137	358
Income taxes paid income taxes received	324	-99 230
income taxes received	324 3.129	3.800
. Cash flow from investing activities	5.125	0.000
	0	(
Cash received from disposal of property, plant and equipment / intangible assets Cash paid for investments in property, plant and equipment / intangible assets	-2.470	-2.766
Cash paid for investments in financial assets	88	-83
Cash paid for investments in associated companies	0	1.746
Cash received disposal of securities	5.204	12.67
Cash paid for investments in securities	-6.408	-13.696
	-3.586	-2.128
. Cash flow from financing activities		
Aquistion of treasury shares	0	
Inflows from minority shareholders as part of capital increase	0	-31
	0	-31
. Cash and cash equivalents at end of period		
Cash relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	-457	1.641
Change in currency conversion adjustment	0	79
Cash and cash equivalents at beginning of fiscal year	3.238	2.772
	2.781	4.492
. Composition of cash and cash equivalents		
cash on hands	2.984	4.620
Bank liabilities due on demand	-203	-128
	2.781	4.492

### Facts and Figures Development of Group Equity of September 30, 2005 and September 30, 2004 (IFRS)

	Subscribed capital KEUR	Capital reserves KEUR	Other provisions KEUR	Equity difference from currency conversion KEUR	Reserve for finacial instruments KEUR	Consolidated loss carry forward KEUR	Consolidated deficit KEUR	Equity KEUR	Authorized capital KEUR
Consolidated equity as of 01/01/2004 according to IFRS	10.292	35.025			24	-10.107	-1.092	34.142	5.146
Transfer of 2003 consolidated loss to consolidate loss cany-forward	-	-	-	_	-	-1.093	1.092	-1	
Increase of equity due to issue of new shares	3.428	3.873	-	-	-	-	-	7.301	-3.428
Equity difference from currency conversion with Nexus Vedizinsoftware und Systemne AG	-	-	-	7	-	-	-	7	
Valuation of financial instruments at Fair Value	-	-	-	-	31	-	-	31	
Consolidated deficit September 30th, 2004	_	-	-	-	-	-	-822	-822	-
Consolidated equity as of 09/30/2004	13.720	38.898	1	6	55	-11.200	-822	40.658	1.718
Consolidated equity as of 01/01/2005 according to IFRS	13.7 <b>2</b> 0	38.898	1	3	75	-11.199	-473	41.025	1.718
Transfer of 2004 consolidated loss to consolidate oss carry-forward	-	-	-	-	-	-473	473	0	
Equity difference from currency conversion with Nexus Vedizinsoftware und Systeme AG	-	-	-	1	-	-	-	1	
Valuation of financial instruments at Fair Value	-	-	-	-	8	-	-	8	
costs of capital increase	-	-44	_	-	-	-	-	-44	
Increase Authorized capital shareholders meeting 06/27/05	-	-	-	-	-	-	-	0	5.142
Consolidated profit September 30th, 2005	-	-	-	-	-	-	21	21	-
Consolidated equity as of 09/30/2005	13.720	38.854	1	4	83	-11.672	21	41.011	6.860



#### e-health solutions

NEXUS AG, Auf der Steig 6, D-78052 Villingen-Schwenningen, Tel +49 (0)7721 8482-0 Fax +49 (0)7721 8482-888, www.nexus-ag.de, mail@nexus-ag.de

NEXUS Medizinsoftware und -systeme AG, Wydenmöösli Strasse 20, CH-8280 Kreuzlingen Tel +41 (0)71 6885-891, Fax +41 (0)71 6885-889, info@nexus-schweiz.ch, www.nexus-schweiz.ch

NEXUS Digitale Dokumentationssysteme Projektentwicklungsges. m.b.H., Güpferlingstr. 29, A-1170 Wien Tel +43 (0)1 3200567, Fax +43 (0)1 3200567-25, info@nexus-ag.de, www.nexus-ag.de

NEXUS Italia SRL, Via della Salute, 18/3, I-40132 Bologna, Tel +39 (0)51 6419098, Fax +39 (0)51 6414947 info@nexus-ag.it, www.nexus-ag.it

### nexus/gmt

women's health solutions

NEXUS / GMT GmbH, Ziegelhüttenweg 45, D-60598 Frankfurt am Main, Tel +49 (0)69 630009-0 Fax +49 (0)69 634410, info@nexus-gmt.de, www.nexus-gmt.de

### nexus/inovit

radiology solutions

NEXUS / INOVIT GmbH, Carl-Zeiss-Ring 13, D-85737 Ismaning, Tel +49 (0)89 962418-0 Fax +49 (0)89 962418-99, info@nexus-inovit.de, www.nexus-inovit.de

### nexus/it

service solutions

NEXUS / IT GmbH, Auf der Steig 6, D-78052 Villingen-Schwenningen, Tel +49 (0)7721 8482-0 Fax +49 (0)7721 8482-334, www.nexus-it.de, mail@nexus-it.de

### nexus/medicare

#### psychiatry solutions

NEXUS / MEDICARE GmbH, Carl-Zeiss-Ring 13, D-85737 Ismaning, Tel +49 (0)89 451500-0 Fax +49 (0)89 451500-50, info@nexus-medicare.de, www.nexus-medicare.de